Shaheenah Dawood

Summary

Publications

  1. doi request reprint Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study
    Shaheenah Dawood
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 117:1819-26. 2011
  2. doi request reprint Biomarker discordance pre and post neoadjuvant chemotherapy in breast cancer
    Shaheenah Dawood
    Department of Medical Oncology, Dubai Hospital, Dubai, UAE
    Cancer Biomark 12:241-50. 2012
  3. doi request reprint Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer
    Shaheenah Dawood
    Department of Medical Oncology, Dubai Hospital, United Arab Emirates
    Cancer 118:4652-9. 2012
  4. doi request reprint Identifying factors that impact survival among women with inflammatory breast cancer
    S Dawood
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
    Ann Oncol 23:870-5. 2012
  5. doi request reprint Novel biomarkers of metastatic cancer
    Shaheenah Dawood
    Department of Medical Oncology, Dubai Hospital, Dubai Health Authority, Dubai, United Arab Emirates
    Expert Rev Mol Diagn 10:581-90. 2010
  6. doi request reprint Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?
    Shaheenah Dawood
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 113:2422-30. 2008
  7. doi request reprint Defining prognosis for women with breast cancer and CNS metastases by HER2 status
    S Dawood
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Oncol 19:1242-8. 2008
  8. doi request reprint Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes
    Shaheenah Dawood
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 27:220-6. 2009
  9. ncbi request reprint Development of new cancers in patients with DCIS: the M.D. Anderson experience
    Shaheenah Dawood
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 15:244-9. 2008
  10. ncbi request reprint Integrating circulating tumor cell assays into the management of breast cancer
    Shaheenah Dawood
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Curr Treat Options Oncol 8:89-95. 2007

Detail Information

Publications43

  1. doi request reprint Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study
    Shaheenah Dawood
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 117:1819-26. 2011
    ....
  2. doi request reprint Biomarker discordance pre and post neoadjuvant chemotherapy in breast cancer
    Shaheenah Dawood
    Department of Medical Oncology, Dubai Hospital, Dubai, UAE
    Cancer Biomark 12:241-50. 2012
    ....
  3. doi request reprint Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer
    Shaheenah Dawood
    Department of Medical Oncology, Dubai Hospital, United Arab Emirates
    Cancer 118:4652-9. 2012
    ..This retrospective study sought to define the incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer (TNBC)...
  4. doi request reprint Identifying factors that impact survival among women with inflammatory breast cancer
    S Dawood
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
    Ann Oncol 23:870-5. 2012
    ..The objective of this retrospective study was to determine factors impacting survival among women with inflammatory breast cancer (IBC)...
  5. doi request reprint Novel biomarkers of metastatic cancer
    Shaheenah Dawood
    Department of Medical Oncology, Dubai Hospital, Dubai Health Authority, Dubai, United Arab Emirates
    Expert Rev Mol Diagn 10:581-90. 2010
    ..DNA- and RNA-based biomarkers have also been identified. This review will focus on some of the novel biomarkers that have been developed over the last decade...
  6. doi request reprint Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?
    Shaheenah Dawood
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 113:2422-30. 2008
    ..The aim of the current study was to assess the prognostic value of baseline circulating tumor cells (CTCs) in a large cohort of patients with newly diagnosed metastatic breast cancer (MBC)...
  7. doi request reprint Defining prognosis for women with breast cancer and CNS metastases by HER2 status
    S Dawood
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Oncol 19:1242-8. 2008
    ....
  8. doi request reprint Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes
    Shaheenah Dawood
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 27:220-6. 2009
    ..The goal of this study was to describe the effect of race on pathologic complete response (pCR) rates and survival outcomes in women with triple receptor-negative (TN) breast cancers...
  9. ncbi request reprint Development of new cancers in patients with DCIS: the M.D. Anderson experience
    Shaheenah Dawood
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 15:244-9. 2008
    ..The purpose of this study was to describe clinical characteristics and outcome of mammographically and clinically detected new cancers in patients with previously diagnosed ductal carcinoma in situ (DCIS)...
  10. ncbi request reprint Integrating circulating tumor cell assays into the management of breast cancer
    Shaheenah Dawood
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Curr Treat Options Oncol 8:89-95. 2007
    ..Large prospective trials are needed to further understand its biology and confirm its role as a predictive and prognostic marker before we can incorporate it into the conventional staging system...
  11. pmc Survival differences among women with de novo stage IV and relapsed breast cancer
    S Dawood
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Oncol 21:2169-74. 2010
    ..The objective of this retrospective study was to determine whether differences in survival exist between women with de novo stage IV and relapsed breast cancer...
  12. doi request reprint Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data
    Selin Carkaci
    Department of Diagnostic Radiology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    J Nucl Med 50:231-8. 2009
    ..Our objective was to retrospectively evaluate 18F-FDG PET/CT in the initial staging of inflammatory breast cancer (IBC)...
  13. pmc Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer
    Shaheenah Dawood
    Department of Breast Medical Oncology and Quantitative Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 26:4891-8. 2008
    ..The aim of this study was to evaluate trends in and factors affecting survival in a large population-based cohort of patients with newly diagnosed stage IV breast cancer...
  14. doi request reprint Prognostic significance of HER-2 status in women with inflammatory breast cancer
    Shaheenah Dawood
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Cancer 112:1905-11. 2008
    ..The purpose of this study was to define the prognostic impact of HER-2 status on survival outcomes of patients with IBC...
  15. ncbi request reprint Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience
    Shaheenah Dawood
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:1195-200. 2007
    ..The purpose of this study was to review the efficacy and safety of a similar regimen outside the setting of a clinical trial...
  16. doi request reprint Impact of body mass index on survival outcome among women with early stage triple-negative breast cancer
    Shaheenah Dawood
    Department of Medical Oncology, Dubai Hospital, United Arab Emirates
    Clin Breast Cancer 12:364-72. 2012
    ..The aim of this retrospective study was to examine the prognostic impact of obesity among women with early stage triple receptor-negative breast cancer (TN), a subtype of breast cancer known to be associated with poor prognosis...
  17. pmc Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes
    Elizabeth A Mittendorf
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 15:7381-8. 2009
    ..To evaluate HER2 status in residual tumor identified at the time of surgery in patients not achieving a pathologic complete response (pCR) and to determine the effect of alterations in HER2 status on recurrence-free survival (RFS)...
  18. doi request reprint Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer
    Ugo De Giorgi
    The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    J Clin Oncol 27:3303-11. 2009
    ..In this study, we compared the prognostic value of CTC and FDG-PET/CT monitoring during systemic therapy for metastatic breast cancer (MBC)...
  19. pmc Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review
    Shaheenah Dawood
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 28:92-8. 2010
    ..CONCLUSION Our results show that women with HER2/neu-positive disease who received trastuzumab had improved prognosis compared with women with HER2/neu-negative disease...
  20. doi request reprint Prognostic value of initial clinical disease stage after achieving pathological complete response
    Shaheenah Dawood
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030 4009, USA
    Oncologist 13:6-15. 2008
    ..Overall, patients who achieved a pCR had a low rate of recurrence. However, higher clinical stage and IBC were associated with worse outcomes in breast cancer patients who achieved a pCR after PST...
  21. doi request reprint Prognostic value of body mass index in locally advanced breast cancer
    Shaheenah Dawood
    Department of Breast Medical Oncology, Division of Quantitative Sciences, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:1718-25. 2008
    ..The analysis includes the subsets of inflammatory (IBC) and noninflammatory (non-IBC LABC) breast cancer...
  22. ncbi request reprint Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women
    Wei Tse Yang
    Department of Diagnostic Radiology, The University of Texas M D Anderson Cancer Center, Houston, TX, 77230, USA
    Breast Cancer Res Treat 111:405-10. 2008
    ..The aim of this study was to compare the mammographic breast density, visibility, and tumor features of different breast cancer immunophenotypes...
  23. doi request reprint Glutathione-s-transferase-pi expression in early breast cancer: association with outcome and response to chemotherapy
    Banu K Arun
    Departments of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, USA
    Cancer Invest 28:554-9. 2010
    ..055). Further studies should evaluate the role of GST-pi expression in relation to response to different chemotherapies...
  24. pmc Prognostic factors of survival in the trastuzumab era among women with breast cancer and brain metastases who receive whole brain radiotherapy: a single-institution review
    Shaheenah Dawood
    Department of Medical Oncology, Dubai Hospital, Dubai, United Arab Emirates
    Cancer 116:3084-92. 2010
    ..The objective of this study was to review the outcome of women with breast cancer with known receptor status who were treated with whole brain radiotherapy for brain metastases and to determine factors that impact survival...
  25. doi request reprint Chronic thyroiditis in patients with advanced breast carcinoma: metabolic and morphologic changes on PET-CT
    Ukihide Tateishi
    Department of Nuclear Medicine, University of Texas, MD Anderson Cancer Center, Houston, TX, USA
    Eur J Nucl Med Mol Imaging 36:894-902. 2009
    ..To investigate clinical implications of FDG uptake in the thyroid glands in patients with advanced breast carcinoma by comparing metabolic and morphologic patterns on positron emission tomography (PET)/computed tomography (CT)...
  26. doi request reprint The medical treatment of inflammatory breast cancer
    Shaheenah Dawood
    Department of Medical Oncology, Dubai Hospital, Dubai, United Arab Emirates
    Semin Oncol 35:64-71. 2008
    ..Improved understanding of the biological features of the disease has allowed for the development of targeted therapies (eg, trastuzumab and lapatinib) that are changing the outcome of this aggressive disease...
  27. ncbi request reprint Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden
    Massimo Cristofanilli
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Breast Cancer 7:471-9. 2007
    ..We compared the prognostic significance of CTCs with clinical and laboratory measures of tumor burden and phenotypic subtype of disease...
  28. pmc Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer
    Michelle M Kim
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Cancer 118:4936-43. 2012
    ..In this study, the role of HR and HER2 status on the locoregional benefit of trastuzumab treatment was investigated in patients with nonmetastatic breast cancer...
  29. pmc Trastuzumab in Primary Inflammatory Breast Cancer (IBC): High Pathological Response Rates and Improved Outcome
    Shaheenah Dawood
    Departments of Breast Medical Oncology, Pathology, Quantitative Sciences, Radiotherapy and Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas and Department of Medical Oncology, Dubai Hospital, Dubai, UAE
    Breast J . 2010
    ..CXCR4 may represent a novel therapeutic target...
  30. doi request reprint Trastuzumab administration associated with change in HER2 status
    Shaheenah Dawood
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Clin Breast Cancer 8:366-9. 2008
    ..We present the unusual case of a patient with HER2/neu-positive stage I breast cancer who, after receiving adjuvant trastuzumab, relapsed to develop HER2/neu-negative metastatic disease...
  31. doi request reprint The use of bevacizumab among women with metastatic breast cancer: a survey on clinical practice and the ongoing controversy
    Shaheenah Dawood
    Department of Medical Oncology, Dubai Hospital, Dubai, United Arab Emirates
    Cancer 118:2780-6. 2012
    ....
  32. doi request reprint Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT
    Ukihide Tateishi
    Department of Nuclear Medicine, University of Texas M D Anderson Cancer Center, Unit 1263, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Radiology 247:189-96. 2008
    ..To retrospectively compare morphologic and metabolic changes in bone metastases in response to systemic therapy in patients with metastatic breast cancer (MBC) with integrated positron emission tomography (PET)/computed tomography (CT)...
  33. doi request reprint Invasive paget disease of the breast: clinicopathologic study of an underrecognized entity in the breast
    Xiuzhen Duan
    Department of Pathology, The University of Texas Health Science Center Department of Pathology, Houston, TX 77030, USA
    Am J Surg Pathol 36:1353-8. 2012
    ..Further studies are required to determine whether invasion in MPD has clinical significance...
  34. ncbi request reprint Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings
    Wei T Yang
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1350, Houston, TX, 77030, USA
    Breast Cancer Res Treat 109:417-26. 2008
    ..To describe the role of Positron Emission Tomography/Computed Tomography (PET/CT), Magnetic Resonance Imaging (MRI), sonography, and mammography in patients with inflammatory breast cancer (IBC)...
  35. pmc Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study
    Shaheenah Dawood
    Department of Breast Medical Oncology, Dubai Hospital, Dubai, UAE
    Breast Cancer Res Treat 126:185-92. 2011
    ..This method may provide a cost-effective means of determining prognosis in the clinical setting...
  36. ncbi request reprint What progress have we made in managing inflammatory breast cancer?
    Shaheenah Dawood
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Oncology (Williston Park) 21:673-9; discussion 679-80, 686-7. 2007
    ..This review examines the limitations of the current definition of IBC, explores our current understanding of the biology of IBC, and reviews the many exciting advances in locoregional and systemic treatment of IBC...
  37. doi request reprint Progress in the biological understanding and management of breast cancer-associated central nervous system metastases
    Shaheenah Dawood
    Departments of Breast Medical Oncology and Systems Biology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Oncologist 18:675-84. 2013
    ....
  38. doi request reprint Biology and management of inflammatory breast cancer
    Shaheenah Dawood
    Department of Medical Oncology, Dubai Health Authority, PO Box 8179, Dubai, UAE
    Expert Rev Anticancer Ther 10:209-20. 2010
    ....
  39. ncbi request reprint Inflammatory breast cancer: what progress have we made?
    Shaheenah Dawood
    Department of Medical Oncology, Dubai Hospital, Dubai Health Authority, United Arab Emirates
    Oncology (Williston Park) 25:264-70, 273. 2011
    ..Our review focuses on the progress made in the field of IBC research over the last decade, with particular attention to advances in the areas of epidemiology, molecular biology, arid clinical management...
  40. doi request reprint Molecular pathways: targeting hsp90--who benefits and who does not
    Maurizio Scaltriti
    Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA
    Clin Cancer Res 18:4508-13. 2012
    ..Several ongoing studies testing different combinations of Hsp90 inhibitors with other targeted agents will confirm whether Hsp90 inhibition can potentiate the efficacy of targeted therapy and/or prevent the emergence of drug resistance...
  41. doi request reprint Pharmacology and pharmacogenetics of chemotherapeutic agents
    Shaheenah Dawood
    Department of Oncology, Dubai Hospital, Dubai, United Arab Emirates
    Cancer Invest 27:482-8. 2009
    ..In addition we will review the pharmacological and pharmacogenetic predictors of toxic effects of chemotherapeutic agents drawing on examples of commonly used agents in oncology...
  42. doi request reprint Triple-negative breast cancer: epidemiology and management options
    Shaheenah Dawood
    Department of Medical Oncology, Dubai Hospital, Dubai Health Authority, Dubai, United Arab Emirates
    Drugs 70:2247-58. 2010
    ..This review focuses on the epidemiology of TNBC, its pathological features, natural history and recurrence patterns as well as current and future management options...
  43. ncbi request reprint Classic Kaposi's sarcoma presenting first with gastrointestinal tract involvement in a HIV-negative Inuit male--a case report and review of the literature
    Brinda Balachandra
    Department of Pathology McGill University Health Centre Montreal General Hospital, 1650 Cedar Ave, Montreal, Quebec, Canada H3G 1A4
    Pathol Res Pract 202:623-6. 2006
    ..We report the first case of classic KS presenting in the gastrointestinal tract of an elderly HIV-negative Inuit male from Northern Quebec, Canada...